Vela Diagnostics is promoting the additional pooling capability of its ViroKey SARS-CoV-2 RT-PCR test, which received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) in 2020.
The FDA's nod means that ViroKey can now be used to detect SARS-CoV-2 RNA from pooled nasal swab samples from up to three people, both symptomatic and asymptomatic. Combining three samples to be tested as one uses fewer testing resources, reducing costs and improving laboratory efficiency.
